Call us today: +1 (304) 470-2225
You can use WPML or Polylang and their language switchers in this area.


Mellalta Meets How Nanobiotix's Breakthrough NBTXR3 is Poised to Radically Transform the LA-HNSCC Landscape

How Nanobiotix’s Breakthrough NBTXR3 is Poised to Radically Transform the LA-HNSCC Landscape?

Locally Advanced Head and neck Cancer (LA-HNSCC) represents a significant clinical challenge. The standard of care (SOC) typically involves a combination of surgery, chemotherapy, and radiation therapy. However, there are significant limitations associated with these […]

Read More
Mellalta Meets: Xevinapant Takes the Lead in LA-HNSCC

Xevinapant Takes the Lead: Merck’s Bold Market Strategies to Outshine Rivals in LA-HNSCC !

For patients with unresected Locally Advanced Head & Neck Cancer (LA-SCCHN) who cannot undergo surgical resection, the current standard of care is high-dose cisplatin-based CRT which has shown to improve locoregional control, PFS and OS compared […]

Read More
Watch 2023 Actinium Pioneering Strategies_Mellalta Meets

Revealed: Actinium KOLs Engagement and Pioneering Strategies for Iomab-B and Actimab-A

As Actinium forges ahead with its transformative therapies, including Iomab-B and Actimab-A, its strategic approach extends beyond clinical trials and regulatory milestones. Actinium’s presentation of six abstracts at the Society for Nuclear Medicine and Molecular […]

Read More